Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Prognostic value of visceral plural invasion limited in part-solid lung cancer

Visceral plural invasion is a significant predictor of survival in patients with small solid lung tumours but not in patients with part-solid tumours, Japanese study findings indicate.

23 Jul 2014

Combined risk score enhances radiation pneumonitis prediction

Combining dose-volume histogram parameters with age and baseline pulmonary fibrosis score creates a novel predictive risk score that improves prediction of radiation pneumonitis in patients receiving concurrent chemoradiotherapy for non-small-cell lung cancer, research shows.

23 Jul 2014

Standard TFI definition still applies for relapsed SCLC classification

Italian researchers have confirmed that using a treatment-free interval cut-off of 60 days to classify relapsed small-cell lung cancer as sensitive or resistant can be regarded as the standard definition.

23 Jul 2014

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.

23 Jul 2014

CRIPTO1 role in TKI resistance elucidated

Overexpression of CRIPTO1 may explain intrinsic tyrosine kinase inhibitor resistance in around 10% of patients with non-small-cell lung cancer and endothelial growth factor receptor mutations, research indicates.

23 Jul 2014

ROS1 fusion genes found in young East Asian patients with lung adenocarcinoma

ROS1 fusion genes were successfully detected independent of gender or smoking history in young East Asian patients with lung adenocarcinoma, a histological subgroup in non-small cell lung cancer (NSCLC), using multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) diagnostic tests.

22 Jul 2014

TAZ represents a novel therapeutic target in NSCLC

Patients with non-small-cell lung cancer who express high levels of transcriptional coactivator with PDZ-binding motif may be a clinically distinct subgroup with an unfavourable prognosis, researchers report.

16 Jul 2014

CIP2A pathway involved in erlotinib response

Researchers have identified a novel mechanism, involving the cancerous inhibitor of protein phosphatase 2A pathway, which mediates the anti-tumour effects of erlotinib in non-small-cell lung cancer cells without epidermal growth factor receptor mutations.

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

AZD3965 drug could prove useful in treating small cell lung cancer

Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.

From The University of Manchester 10 Jul 2014

New drug could prove useful in treating small cell lung cancer

Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.

From The University of Manchester 10 Jul 2014

Lung cancer and melanoma funders form first-ever research collaboration

LUNGevity Foundation today announced a partnership with the Lung Cancer Research Foundation and Melanoma Research Alliance to co-fund new innovative research on PD-1 inhibitor treatment options for both non-small cell lung cancer (NSCLC) and metastatic melanoma (MM) patients with brain metastases.

9 Jul 2014

$FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL$

FDA grants Breakthrough Therapy status to Novartis' CTL019 for treatment of relapsed/refractory ALL

Novartis announced today that the United States Food and Drug Administration has granted Breakthrough Therapy status to CTL019, an investigational chimeric antigen receptor (CAR) therapy for the treatment of pediatric and adult patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL).

7 Jul 2014

Lung cancer patients could benefit from new 'QTA' technique

Lung cancer patients could receive more precise treatment, and their progress could be better tracked, using a new high-tech method of non-invasive medical imaging analysis, according to a study published today by the journal PLOS ONE.

3 Jul 2014

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group, the company focused on building quality cancer care, today announces that rights to anamorelin, its innovative ghrelin receptor agonist, have been granted in Turkey to GEN Ilaç.

30 Jun 2014

Surgical biopsies can be safely performed on selected patients with late-stage lung cancer

Researchers at UC Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor (EGFR).

27 Jun 2014

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, today announced plans to move forward with a Phase 2a clinical trial in the U.S. using its formulation of EGFR-targeted, EDV nanocells packaged with doxorubicin for the treatment of recurrent glioblastoma (GBM), a common and aggressive type of brain tumor.

26 Jun 2014

Intercalated erlotinib–eribulin ‘feasible’ without added efficacy

Erlotinib can be intercalated with the anti-tubule agent eribulin mesylate for patients with advanced non-small-cell lung cancer but it is unlikely to increase treatment efficacy in those without epidermal growth factor receptor activating mutations, research suggests.

25 Jun 2014

New study explores effects of immunotherapy, chemotherapy drugs on non-small cell lung cancer

A new study offered at Houston Methodist Hospital will compare an emerging immunotherapy drug to an existing chemotherapy drug and look at the effects both drugs have on the development of non-small cell lung cancer, a type of cancer which makes up about 85 percent of lung cancer cases.

24 Jun 2014